Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenalisib in Relapsed/Refractory T-cell Lymphoma
NCT02567656Phase 1Completed
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Sep 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenalisib in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), sponsored by Rhizen Pharmaceuticals AG. Primary endpoint: Safety of RP6530 at 28 days. Started Sep 2015; status: completed.
02
Drugs
tenalisib
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02567656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567656.